Biotech offers thrills as well as spills. Last week’s $9.7bn offer from Novartis catapulted shares in US biotech Medco to nearly four times their value a year ago. For early investors it was a reward for patience. The shares went nowhere much of the previous 20 years.

In this sector many are called, few are chosen. Biotechs are more likely to be bought out pricily — the ultimate mark of success — if a blockbuster drug is close to winning approval, or has won that validation.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now